Answers are grounded in this paper and cite their sources.
Higher levels of functionally exhausted HBV-specific CD8 T cells are associated with a lack of response that cannot be restored by blocking the PD-1:PD-L1 axis. This suggests that the clinical effectiveness of blocking the PD-1:PD-L1 axis as a monotherapy may be restricted. Combination strategies, potentially including the combination of anti-LAG-3 with other anti-iR antibodies, will likely be required to elicit a functional cure for patients with high levels of functionally exhausted HBV-specific CD8 T cells.
No takes yet. Share an insight, caveat, or question.
Ferrando‐Martínez et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: